
Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Your AI-Trained Oncology Knowledge Connection!


Kimberly Perez, MD is the Co-Director, Clinical Research, Division of Gastrointestinal Oncology, and an Assistant Professor of Medicine at Harvard Medical School.

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Published: May 14th 2025 | Updated: